Search Result

Results for "

flt3+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (6) Apoptosis (43) Bcl-2 Family (1) Btk (1) c-Kit (6) Caspase (4) CDK (2) ERK (6) FLT3 (86) Haspin Kinase (1) HSP (1) IRAK (1) Isotope-Labeled Compounds (2) JAK (8) Ligands for Target Protein for PROTAC (1) Mitochondrial Metabolism (1) p38 MAPK (1) PARP (1) PDGFR (4) PI3K (1) PROTACs (2) Reactive Oxygen Species (ROS) (2) Reference Standards (4) STAT (6) Syk (8) TAM Receptor (1) Tie (1)
By Research Areas:	Cancer (85) Cardiovascular Disease (1) Inflammation/Immunology (9) Neurological Disease (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13038A

Fostamatinib 10+ Cited Publications R788	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive *Syk/FLT3* inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) ^[3].

HY-13001

Quizartinib Maximum Cited Publications 45 Publications Verification AC220	FLT3 Apoptosis PDGFR c-Kit	Cancer
Quizartinib (AC220) is an orally active, potent and selective *FLT3* inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .

HY-12067

R406 35+ Cited Publications	Syk FLT3 Apoptosis	Inflammation/Immunology Cancer
R406 is an orally available and competitive *Syk/FLT3* inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-12344

UNC2025 5+ Cited Publications	FLT3	Neurological Disease Cancer
UNC2025 is a potent, ATP-competitive, highly orally active and BBB-permeable *Mer/Flt3* inhibitor with IC₅₀ values of 0.74 nM and 0.8 nM, respectively. UNC2025 is >45-fold selectivity for MERTK relative to Axl (IC₅₀= 122 nM; K_i = 13.3 nM). UNC2025 exhibits an excellent PK properties, and can be used for the investigation of acute leukemia ^[3].

HY-130247

Flonoltinib 1 Publications Verification JAK2/flt3-IN-1	JAK FLT3 Apoptosis	Cancer
Flonoltinib is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity .

HY-13038

Fostamatinib Disodium 10+ Cited Publications R788Disodium	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406 . R406 is an orally available and competitive *Syk/FLT3* inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) ^[3].

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective *FLT3* inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells ^[3].

HY-11108

R406 free base 35+ Cited Publications	Syk FLT3 Apoptosis	Inflammation/Immunology Cancer
R406 free base is an orally available and competitive *Syk/FLT3* inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-12494

LDC1267 5+ Cited Publications	TAM Receptor FLT3	Neurological Disease Cancer
LDC1267 is a *AXL/TAM/FLT3* inhibitor with IC₅₀ values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia ^[3].

HY-13038B

Fostamatinib disodium hexahydrate 10+ Cited Publications R788 disodium hexahydrate	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406 . R406 is an orally available and competitive *Syk/FLT3* inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) ^[3].

HY-12960

SKLB4771 flt3-IN-1	FLT3 c-Kit Apoptosis	Cancer
SKLB4771 is a potent and selective Flt3 inhibitor with an IC₅₀ value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue .

HY-14217

Quizartinib dihydrochloride Maximum Cited Publications 45 Publications Verification AC220 dihydrochloride	FLT3 Apoptosis PDGFR c-Kit	Cancer
Quizartinib (AC220) dihydrochloride is an orally active, potent and selective *FLT3* inhibitor. Quizartinib dihydrochloride inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib dihydrochloride inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib dihydrochloride can be used for the research of cancer .

HY-12333

Denfivontinib 2 Publications Verification G-749	FLT3 Apoptosis	Cancer
Denfivontinib (G-749) is a potent, oral active and ATP competitive *FLT3* inhibitor, with IC₅₀s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. Denfivontinib can be used for the research of agent resistance for acute myeloid leukemia (AML) .

HY-15166B

(E/Z)-Zotiraciclib citrate 5+ Cited Publications (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and *FLT3* inhibitor .

HY-112145

FLT3-IN-3 3 Publications Verification	FLT3	Cancer
FLT3-IN-3 is a potent *FLT3* inhibitor with IC₅₀s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.

HY-13907

TCS 359 1 Publications Verification	FLT3	Cancer
TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent and selective *FLT3* inhibitor with an IC₅₀ of 42 nM. TCS 359 inhibits MV4-11 cell proliferation with an IC₅₀ of 340 nM .

HY-15003

ATH686	FLT3 Apoptosis	Cancer
ATH686 is a potent, selective and ATP-competitive *FLT3* inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects .

HY-12344A

UNC2025 hydrochloride 5+ Cited Publications	FLT3	Cancer
UNC2025 hydrochloride is a potent, ATP-competitive, highly orally active and BBB-permeable *Mer/Flt3* inhibitor with IC₅₀ values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC₅₀= 122 nM; K_i = 13.3 nM). UNC2025 hydrochloride exhibits an excellent PK properties, and can be used for the investigation of acute leukemia .

HY-118304B

AKN-028 acetate	FLT3 Apoptosis Caspase	Cancer
AKN-028 acetate, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN-028 acetate induces dose-dependent cytotoxic response (mean IC50=1 μM). AKN-028 acetate induces apoptosisby activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML).

HY-13537

BPR1J-097	FLT3	Cancer
BPR1J-097 is a novel potent *FLT3* inhibitor with an IC₅₀ of 11 nM.

HY-112475

Flt-3 Inhibitor III	Tie FLT3	Cancer
Flt-3 Inhibitor III is a potent and selective FLT3 kinase inhibitor with an ₅₀ of 50 nM. Flt-3 Inhibitor III shows less active against other kinases. Flt-3 Inhibitor III has anticancer effects .

HY-130247A

Flonoltinib TFA 1 Publications Verification JAK2/flt3-IN-1 TFA	JAK FLT3 Apoptosis	Cancer
Flonoltinib TFA is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity .

HY-18949

JI6	FLT3 JAK c-Kit	Cancer
JI6 is a potent, selective and orally active *FLT3* inhibitor, with IC₅₀s of ～40, 8, and 4 nM for *FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits* *JAK3* and c-Kit, with IC₅₀s of ～250 and ～500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia .

HY-153473

FLT3-IN-19	FLT3	Cancer
FLT3-IN-19 (Comp 50) is a potent and selective *FLT3* inhibitor with IC₅₀ of 0.213 nM. FLT3-IN-19 can be used in AML disease research .

HY-18952A

(Z)-SU5614	FLT3 Apoptosis	Cancer
(Z)-SU5614 is a potent *FLT3* inhibitor and selectively induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3 .

HY-16449

SB1578 CT-1578	JAK FLT3	Inflammation/Immunology
SB1578 (CT-1578) is a selective JAK2 and *FLT3* inhibitor with an IC₅₀ of 46 nM and 60 nM, respectively. SB1578 exhibits high selectivity for other kinase targets. SB1578 can be used for the study of non-oncology indication rheumatoid arthritis .

HY-178908

FLT3-IN-35	FLT3 Apoptosis	Cancer
FLT3-IN-35 (Compound 4K) is an orally active, covalent, irreversible *FLT3* inhibitor. FLT3-IN-35 inhibits the phosphorylation of FLT3 and its downstream signaling factors, as well as induces cell cycle arrest and apoptosis. FLT3-IN-35 inhibits the phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis. FLT3-IN-35 can be used for the study of acute myeloid leukemia (AML) .

HY-144869

OTS447	FLT3	Cancer
OTS447 is a potent *FLT3* inhibitor with an IC₅₀ of 21 nM (WO2012016082A1, compound 335) .

HY-103464

5'-Fluoroindirubinoxime 5'-FIO	FLT3	Cancer
5'-Fluoroindirubinoxime (5’-FIO, compound 13), an Indirubin (HY-N0117) derivative, is a potent *FLT3* inhibitor, with an IC₅₀ of 15 nM .

HY-18744

FLT3-IN-2	FLT3	Cardiovascular Disease Cancer
FLT3-IN-2 (Compound P-0266) is a *FLT3* inhibitor with an IC₅₀ of < 1 μM. FLT3-IN-2 can be used in acute myeloid leukemia research .

HY-111249

TTT 3002	FLT3	Cancer
TTT 3002 is a potent and orally active *FLT3* inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC₅₀ of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research .

HY-160787

NCGC1481	FLT3 IRAK	Cancer
NCGC1481 is an inhibitor of *FLT3, IRAK1, and IRAK4, with IC₅₀* values of <0.5 nM, 22.6 nM, and 0.8 nM, respectively. NCGC1481 can effectively overcome the adaptive resistance of leukemia cells to *FLT3* inhibitors and has antileukemic activity .

HY-151961

RSH-7	Btk FLT3	Cancer
RSH-7 is a potent BTK and *FLT3* inhibitor with IC₅₀s of 47, 12 nM, respectively. RSH-7 induces apoptosis and shows antiproliferative activities. RSH-7 inhibits BTK and FLT3 signaling and shows anti-tumor activity .

HY-115443

MZH29	FLT3	Cancer
MZH29 is a potent and orally active *FLT3* inhibitor. MZH29 shows inhibitory effects on wild-type and mutant FLT3, including the FLT3-ITD, FLT3-D835H/Y/V and FLT3-K663Q mutants. MZH29 retains its potent inhibitory effect against the FLT3-ITD/F691L mutation, a drug resistance mutation against the well-known FLT3 inhibitor, AC220 (HY-13001). MZH29 can be used for the research of cancer, such as acute myeloid leukemia (AML) .

HY-178444

Flt-3-IN-1	FLT3 Apoptosis	Cancer
Flt-3-IN-1 is a potent *FLT-3* inhibitor with an IC₅₀ of 0.91 μM. Flt-3-IN-1 can cause leukemia cells G1 phase arrest and induce apoptosis. Flt-3-IN-1 can be used for the research of cancer, such as leukemia .

HY-130247B

Flonoltinib monomaleate JAK2/flt3-IN-1 monomaleate	JAK FLT3 Apoptosis	Cancer
Flonoltinib maleate is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .

HY-125051

SG3-179	JAK FLT3	Cancer
SG3-179 is a potent inhibitor against the BET bromodomain proteins. SG3-179 is also a JAK2 and *FLT3* inhibitor. SG3-179 causes a rapid reduction in HOXB13 protein expression. SG3-179 is promising for research of multiple myeloma (MM1.S) .

HY-13038AR

Fostamatinib (Standard) R788 (Standard)	Reference Standards Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib (Standard) is the analytical standard of Fostamatinib. This product is intended for research and analytical applications. Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive *Syk/FLT3* inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) ^[3].

HY-13001R

Quizartinib (Standard) AC220 (Standard)	Reference Standards FLT3 Apoptosis PDGFR c-Kit	Cancer
Quizartinib (AC220) (Standard) is the analytical standard of Quizartinib (HY-13001). This product is intended for research and analytical applications. Quizartinib is an orally active, potent and selective *FLT3* inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .

HY-175274

MolPort-002-705-878	FLT3	Cancer
MolPort-002-705-878 is a highly selective FMS-like tyrosine kinase 3 (FLT3) inhibitor with a binding affinity of −11.33 kcal/mol. MolPort-002-705-878 inhibits the proliferation of FLT3-mutated acute myeloid leukemia (AML) cells. MolPort-002-705-878 is promising for research of FLT3-mutated AML .

HY-125008

JH-IX-179	FLT3 Apoptosis	Cancer
JH-IX-179 is an *FLT3* inhibitor (IC₅₀ = 4 nM (FLT3-ITD), 10 nM (FLT3-D835Y)). JH-IX-179 inhibits G1 phase arrest and induces apoptosis in FLT3-ITD-expressing cells. JH-IX-179 can be used in acute myeloid leukemia (AML) research .

HY-158325

*PROTAC FLT-3* degrader 4**	PROTACs FLT3 Apoptosis	Cancer
PROTAC FLT-3 degrader 4 is an orally active CRBN-based *FLT3-PROTAC* degrader that potently induces FLT3-ITD degradation through the ubiquitin-proteasome system. PROTAC FLT-3 degrader 4 shows highly selective to FLT3-ITD mutant acute myeloid leukemia (AML) cells. (Blue: CRBN ligand, Black: linker; Pink: FLT3 inhibitor) .

HY-118304

AKN-028	FLT3 Apoptosis Caspase	Cancer
AKN-028, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC₅₀ value of 6 nM. AKN-028 inhibits FLT3 autophosphorylation. AKN-028 induces dose-dependent cytotoxic response (mean IC₅₀=1 μM). AKN-028 induces apoptosisby activation of caspase 3. AKN-028 can be used in research of acute myeloid leukemia (AML) .

HY-174911

FLT3-IN-33	FLT3 Apoptosis	Cancer
FLT3-IN-33 (Compound 7r) is a *FLT3* inhibitor with an IC₅₀ of 7.82  nM. FLT3-IN-33 has superior anticancer activities against acute myeloid leukemia (AML) cells, such as MV4-11 and MOLM-13 cells. FLT3-IN-33 significantly induces cell apoptosis and inhibits phosphorylation of FLT3 pathways. FLT3-IN-33 can be used for AML and other cancers research .

HY-178996

FLT3-IN-36	FLT3 Apoptosis Akt ERK PI3K STAT Mitochondrial Metabolism	Cancer
FLT3-IN-36 is a potent *FLT3* inhibitor. FLT3-IN-36 exhibits antitumor activity against FLT3-mutated acute myeloid leukemia (AML) cells. FLT3-IN-36 induces cell cycle arrest, reduces mitochondrial membrane potential, and induces apoptosis, downregulating FLT3 and downstream protein expression (including AKT, ERK, *PI3K, and STAT5). FLT3-IN-36* can be used for AML research .

HY-145015A

Tuspetinib hydrate HM43239 hydrate	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) hydrate is an orally active and selective *FLT3* inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells ^[3].

HY-145015B

Tuspetinib dihydrochloride HM43239 dihydrochloride	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) dihydrochloride is an orally active and selective *FLT3* inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib dihydrochloride inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib dihydrochloride inhibits the proliferation and induces the apoptosis of leukemic cells ^[3].

HY-174437

FLT3-IN-32	FLT3 Apoptosis	Cancer
FLT3-IN-32 is a potent and orally active *FLT3* inhibitor. FLT3-IN-32 shows high selectivity for *FLT3* and efficiently inhibits *FLT3*-activating mutations and induces apoptosis. FLT3-IN-32 shows good tolerability in non-tumor bearing mice. FLT3-IN-32 demonstrates outstanding anti-tumor efficacy in MV4-11 bearing NOD/SCID mice, prolonging the survival noticeably. FLT3-IN-32 can be used for the research of acute myeloid leukemia .

HY-179382

HSB401	FLT3 Apoptosis	Cancer
HSB401 is an orally active *FLT3* inhibitor (IC₅₀: 28, 5, 72, 51 nM for FLT3-WT, FLT3-D835Y, FLT3-ITD-F691L, FLT3-ITD, respectively). HSB401 downregulates FLT3 signaling and induces cell cycle arrest and apoptosis. HSB401 spares c-KIT inhibition, thereby reducing the risk of myelosuppression. HSB401 significantly suppresses tumor growth in the MV4-11 xenograft mouse model. HSB401 can be used for the research of acute myeloid leukemia .

HY-175273

MA191	PROTACs FLT3 HSP ERK STAT Akt Apoptosis	Cancer
MA191 is a *FLT3* PROTAC degrader. MA191 abrogates *FLT3* inhibitor resistance from rebound activation of mitogen-activated kinases. MA191 mediates rapid *FLT3*-ITD degradation through a mechanism requiring VHL, neddylation, and BIM. MA191 reduces *FLT3*-ITD levels before inducing apoptosis. MA191 halts AML cell proliferation in Danio rerio. MA191 can be used for the study of acute myeloid leukemia (AML) (Pink: FLT3 ligand: (HY-175311), Blue: E3 ligase CRBN Ligand (HY-112078), Black: Linker, E3 ligase ligand-linker conjugate (HY-175312)) .

Cat. No.	Product Name	Chemical Structure

HY-148036S

FLT3-IN-16-d1
FLT3-IN-16-d1 is the deuterium labeled FLT3-IN-16 (HY-148036). FLT3-IN-16 is a potent *FLT3* inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-13001S

Quizartinib-d8

Quizartinib (AC220)-d₈ is deuterium labeled Quizartinib (HY-13001). Quizartinib is an orally active, potent and selective FLT3 inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: